Lysophosphatidic acid receptor 1 modulates lipopolysaccharide-induced inflammation in alveolar epithelial cells and murine lungs lysophospholipid; signal transduction; lipopolysaccharide; inflammation; acute lung injury; lysophosphatidic acid receptor 1; interleukin-6 ACUTE LUNG INJURY (ALI) is characterized by acute respiratory failure resulting from destruction of the epithelium-capillary interface, inflammation, and extravasations of protein-rich fluid (14, 26, 35) . The lung epithelium is the site of first contact for both inflammatory and inhaled physical environmental stimuli, acting as a physical barrier between lung interstitium and environment (30, 34) . Disruption of epithelial barrier integrity results in paracellular leakage of relatively large proteins, such as albumin and immunoglobulin G, into alveolar spaces (15, 18, 19) . Thus, the epithelium not only functions as a barrier but also secretes cytokines, chemokines, and lipid mediators to attract and activate a number of resident and infiltrating cells that play a role in airway inflammation (21, 25) . Our previous studies have shown that bronchial epithelial cells release interleukin (IL)-8 (7, 43, 48) , , and prostaglandin E 2 (PGE 2 ) (17, 47) in response to bioactive lipid mediators and lipopolysaccharide (LPS), resulting in the infiltration of neutrophils into alveolar space (7, 47) . The LPS-induced murine model of lung injury has been widely used to investigate mechanisms of ALI (18, 31, 40) . Intratracheal administration of LPS increases protein and cytokine levels in bronchial alveolar lavage (BAL) fluids (18, 31, 40) , whereas LPS challenge of lung endothelial (12, 23, 36) or bronchial epithelial (10, 18) cells enhances both barrier permeability and IL-6 release (3). The LPS-mediated cellular responses, such as activation of nuclear factor-B (NF-B) and phosphorylated (p)-38 MAPK, are through a receptor complex containing CD14 and Toll-like receptor 4 (TLR4) (16, 24, 33, 37) . CD14 is known to be expressed in lipid rafts, which are plasma membrane microdomains that are enriched for cholesterol and sphingomyelin and characterized by insolubility in nonionic detergents (8, 28) . In addition to interaction with LPS, recent studies show that CD14 binds to surfactant proteins (2, 4, 32) and integrin-␤ 1 (22) , suggesting involvement of additional new signaling pathways in CD14-regulated LPS-induced inflammation.
Studies from our group and others show that lysophosphatidic acid (LPA) functions as both a pro-and anti-inflammatory mediator in inflammatory lung diseases (17, 43, (45) (46) (47) . LPA induces IL-8 secretion in human bronchial epithelial cells and promotes infiltration of neutrophils into alveolar space (7, 43, 47, 48) . Tager et al. (38) showed a critical role for LPA and LPA receptor 1 (LPA 1 ) in pathogenesis of pulmonary fibrosis (38) . Furthermore, downregulation of LPA 2 reduced infiltration of eosinophils into airway lumen (47) , suggesting that LPA and LPA receptors may exhibit proinflammatory properties. Also, recent evidence indicates that LPA plays an antiinflammatory role by releasing IL-13 decoy receptor (IL-13R␣ 2 ) (45) and PGE 2 (17) in lung epithelial cells. Intravenous (9) or intratracheal (18) administration of LPA reduces LPSinduced inflammation in the lung. The "Yin and Yang" effect of LPA in lung inflammation may be because of differences in preparations and targets of LPA; however, the roles of endogenous LPA and LPA receptors in LPS-induced acute lung inflammation are not clear.
The objective of this study was to determine the role of LPA receptors in LPS-induced acute lung inflammation. The data show for the first time that interaction between LPA 1 and CD14 regulates LPS-induced lung inflammation. Moreover, LPS increased LPA production and LPA 1 expression in vivo, and knock down of LPA 1 in mice (LPA 1 Ϫ/Ϫ ) attenuated LPS-induced inflammation.
MATERIALS AND METHODS
Materials. 1-Oleoyl (18:1) LPA, Ki16425, LPS (Escherichia coli O127:B8), antibody to ␤-actin, and methyl-␤-cyclodextrin (MBCD) were purchased from Sigma-Aldrich (St. Louis, MO). Antibodies to p-I-B, p-I-B kinase (IKK) ␣/␤, IKK␣/␤, p38 MAPK, and p-p38 MAPK were from Cell Signaling Technology (Beverly, MA). Antibody to CD14 was from Santa Cruz Biotechnology (Santa Cruz, CA). Antibody to LPA 1 was from Lifespan Bioscience (Seattle, WA). Horseradish peroxidase-conjugated goat anti-rabbit, anti-mouse, and realtime RT-PCR reagents were from Bio-Rad Laboratories (Hercules, CA). The enhanced chemiluminescence kit for detection of proteins by Western blotting was obtained from Thermo Fisher Scientific (Waltham, MA). All other reagents were of analytical grade.
Cell culture. The mouse lung epithelial cell line, MLE12, was purchased from American Type Cell Culture (Manassas, VA) and cultured in HITES medium with 10% FBS at 37°C in 5% CO 2. Three hours before experimentation, the normal medium was replaced with serum-free medium.
Small-interfering RNA tranfection. Control small-interfering RNA (siRNA) and LPA 1-3 siRNA were purchased from Santa Cruz Biotechnology. siRNAs (50 nM) was transfected into MLE12 cells by electroporation (51) . After 73 h, cell medium were replaced with serum-free medium, and cells were treated with LPS.
IL-6 measurement. BAL fluids or culture supernatants were centrifuged at 500 g for 10 min to remove cell debris. IL-6 levels were measured using an enzyme-linked immunosorbent assay (ELISA) kit for mouse IL-6 according to the manufacturer's instructions (Invitrogen).
Immunoblotting. Equivalent amounts of cell lysates (20 g protein) were separated by 10% SDS-PAGE, transferred to polyvinylidene difluoride membranes, blocked with 5% (wt/vol) BSA in 25 mM Tris·HCl, pH 7.4, 137 mM NaCl, and 0.1% Tween 20 (TBST) for 1 h, and incubated with antibodies (1:1,000) in 5% (wt/vol) BSA in TBST for 1-2 h at room temperature (RT). The membranes were washed at least three times with TBST at 15-min intervals and then incubated with a horseradish peroxidase-conjugated rabbit or mouse secondary antibody (1:3,000) for 1 h at RT. The membrane was developed with the enhanced chemiluminescence detection system according to the manufacturer's instructions.
Transfection of adenoviral constructs. Infection of MLE12 cells (ϳ60% confluence) with purified empty adenoviral vector and adenoviral vectors of mouse lipid phosphate phosphatase 1 (LPP-1) wild type were carried out in six-well plates as described previously (48) . Following infection with different multiplicity of infection (MOI) in 1 ml of HITES medium for 48 h, the virus-containing medium was replaced with DMEM-F-12 medium, and experiments were performed.
Fluorescence immunostaining. MLE12 cells were grown in a glass chamber and treated with LPS for 2 h. Cells were then fixed with 3.7% of formaldehyde for 20 min, followed by permeabilization with 0.1% of Triton X-100 for 1 min. Localization of LPA1 and CD14 was determined by immunofluorescence staining after incubation with primary antibodies and fluorescence-labeled secondary antibodies. Images were captured by a Nikon ECLIPSE TE 300 inverted microscope. A: MLE12 cells were treated with Ki16425 (1, 5, and 10 M, 1 h) before LPS challenge (10 g/ml, 1 h). Equivalent amounts of cell lysates were subjected to immunoblotting with antibodies against phosphorylated (p)-p38, p-38, p-I-B kinase (IKK), IKK, p-IB, and ␤-actin. Representative blots from 3 independent experiments are shown. DMSO, dimethyl sulfoxide. B: relative expression levels of the above proteins as evidenced from density profiles using image J software. C: MLE12 cells were transfected with control smallinterfering RNA [siRNA (siCont)] or LPA1 siRNA (siLPA1, 50 ng/ml, 72 h) before LPS challenge (10 g/ml) for 1 h. Cell lysates were analyzed by immunoblotting using antibodies against p-p38, p-38, p-IKK, IKK, p-IB, and ␤-actin. Representative blots from 3 independent experiments are shown. D: intensity changes of phosphoproteins in the immunoblots shown in C were analyzed by image J software. Veh, vehicle.
PCR-based genotyping of LPA1
Ϫ/Ϫ mice. The Extract-N-Amp Tissue PCR kit (Sigma-Aldrich) was used for isolating genomic DNA from mouse tail and amplifying LPA1-specific DNA fragments. The primers for LPA 1 knockout mice were described in previous studies (5, 6) .
LPS-induced ALI in a murine model. LPA 1 Ϫ/Ϫ mice were generated as previously described (5, 6). All of the mice were bred and housed in a specific pathogen-free barrier facility maintained by the University of Chicago Animal Resources Center. Adult male, 8-to 10-wk-old mice with an average weight of 20 -25 g were anesthetized with 3-5 ml/kg of anesthesia mixture of ketamine and of xylazine. LPS (5 mg/kg) in PBS or PBS alone was administered intratracheally. After 24 h, lungs were lavaged by an intratracheal injection of 1 ml of PBS solution followed by gentle aspiration; the lavage was repeated two times to recover a total volume of 1.8 -2.0 ml. The recovered BAL fluids were processed for determining protein and IL-6 concentrations. Lungs from control and LPS-challenged mice were collected for histological evaluation by staining with hematoxylin and eosin (H&E). Plasma was collected, and LPA levels were measured by LC-MS/MS. All animal experiments were approved by the University of Chicago Institutional Animal Care & Use Committee (Chicago, IL) and adhered to strict humane treatment of experimental animals.
RNA extraction and real-time RT-PCR. Total RNA was extracted from lung tissue by TRIzol (Sigma) according to the manufacturer's instructions. RNA (1 g) was reverse-transcripted using the cDNA synthesis kit (Bio-Rad), and real-time PCR was performed to assess expression of mouse LPA 1-5 genes using specific primers as previously described (47) . Amplicon expression in each sample was normalized to its 18S RNA content. The relative abundance of target mRNA in each sample was calculated based on the following formula:
where LPAR is LPA receptor. LPA measurement by mass spectrometry. Lipids in plasma were extracted as described (13) . In brief, LPA levels were determined using liquid chromatography and tandem mass spectrometry (LC) with an ABI-4000 Q-TRAP hybrid triple quadrupole/ion trap mass before LPS challenge (10 g/ml, 3 h). IL-6 levels in culture supernatants were measured by enzyme-linked immunosorbent assay (ELISA). B: MLE12 cells were transfected with siCont or siLPA1 (50 ng/ml, 72 h) before LPS challenge (10 g/ml) for 3 h, and IL-6 levels in culture supernatants were measured by ELISA. Inset shows the effect of siLPA1 on expression of LPA1 based on immunoblotting whole cell lysates using anti-LPA1 antibody. Statistical analyses. All results were subjected to statistical analysis using one-way ANOVA and, where appropriate, analyzed by StudentNewman-Keuls test. Data are expressed as means Ϯ SD of triplicate samples drawn from a minimum of three independent experiments, and a value of P Ͻ 0.05 was considered statistically significant.
RESULTS

Involvement of LPA 1 in LPS-induced signaling and IL-6
secretion. MLE12 cells were pretreated with either dimethyl sulfoxide (DMSO, 0.1%) or a LPA 1&3 antagonist, Ki16425 (1-10 M, 1 h), and then challenged with LPS (10 g/ml) for 1 h. Activation of p38 MAPK and NF-B signaling was determined by immunoblotting using specific antibodies. As shown in Fig. 1, A and B, LPS stimulated phosphorylation of p38 MAPK, IKK␣/␤, and I-B in MLE12 cells; however, pretreatment with Ki16425 attenuated LPS-mediated signal transduction of MAPK and NF-B in a dose-dependent manner. LPS treatment had no effect on total p38 MAPK, IKK␣, and ␤-actin expression. To confirm the role of LPA 1 , we abrogated the expression of LPA 1 by transfecting cells with LPA 1 siRNA (50 nM, 72 h) before LPS challenge. Downregulation of LPA 1 expression attenuated LPS-induced phosphorylation of p38 MAPK, IKK␣/␤, and I-B (Fig. 1, C and D) . LPA 1 siRNA transfection reduced LPA 1 expression but had no effect on LPA 2 or LPA 3 expression (Fig. 1C) . LPS induces proinflammatory cytokine release, including IL-6. We next investigated the effects of downregulation or inhibition of LPA 1 on LPS-induced IL-6 secretion in MLE12 cells. Consistent with the conclusion that LPS induces proinflammatory responses, LPS (10 g/ml) significantly increased IL-6 secretion in MLE12 cells. Furthermore, pretreatment with Ki16425 (1-10 M) for 1 h (Fig. 2A) or downregulation of LPA 1 by siRNA (Fig. 2B) reduced LPS-induced IL-6 secretion (25-43%). These results suggest a role of LPA 1 in LPS-mediated IL-6 secretion in mouse alveolar epithelial cells.
Overexpression of LPP1 has no effect on LPS-induced signaling. To investigate mechanisms of LPA 1 -mediated LPS signaling, we first determined the role of LPA in IL-6 secretion Fig. 4 . LPS increases LPA1 interaction with CD14. A: MLE12 cells were incubated with neutralizing CD14 antibody (Ab, 10 g/ml) or an equivalent amount of IgG for 6 h before LPS (10 g/ml, 1 h) challenge. Equivalent amounts of cell lysates were subjected to immunoblotting with antibodies against p-p38, p-38, p-IB, and ␤-actin. Representative blots from 3 independent experiments are shown. B: relative expression levels of the above proteins as evidenced from density profiles using image J software. C: MLE12 cells treated with LPS (1, 10, or 50 g/ml) for 2 h; CD14-containing protein complexes were immunoprecipitated (IP) using a CD14-specific antibody and analyzed by immunoblotting (IB) with antibodies to LPA1 and CD14. Representative blots from 3 independent experiments are shown. D: MLE12 cells were treated with LPS (10 g/ml) for 0.5, 1, and 2 h, CD14 immunoprecipitated with an anti-CD14 antibody, and analyzed for coimmunoprecipitated proteins. Representative blots from 3 independent experiments are shown. E: MLE12 were treated with 5 mM methyl-␤-cyclodextrin (MBCD) for 2 h before LPS challenge (10 g/ml) for 2 h. LPA1 was immunoprecipitated with an anti-LPA1 antibody and analyzed for coimmunoprecipitated proteins. Representative blots from 2 independent experiments are shown. F: MLE12 cells grown on a glass chamber were treated with LPS (10 g/ml) for 2 h, fixed using 3.7% formaldehyde for 20 min, followed by a wash in PBS containing 0.1% Triton for 1 min. LPA1 and CD14 were immunostained with antibodies to LPA1 and CD14. Fluorescence intensity profiles are also shown. Green fluorescence is for LPA1 signal, red fluorescence is for CD14 signal, and blue fluorescence is for nuclei signal. Arrows show colocalization of LPA1 and CD14. Shown are representative data from 3 independent experiments. ajplung.physiology.org in MLE12 cells. MLE12 cells were treated with LPA (0.1-1 M) for 3 h, and IL-6 levels in culture supernatants were measured using an ELISA kit. As shown in Fig. 3A , LPA (0.5 and 1 M) slightly induced IL-6 secretion (ϳ2-fold) to a much lesser extent compared with LPA-induced IL-8 secretion (7, 17) . To investigate whether ligation of LPA to LPA 1 is involved in LPS-induced signaling, overexpression of LPP1, a key enzyme to dephosphorylate LPA to monoacylglycerol (48) , was performed before LPS treatment. Overexpression of myc-tagged LPP1 (5-50 MOI, 24 h) had no effect on LPSinduced phosphorylation of p38 MAPK and I-B (Fig. 3, B and  C) ; however, overexpression of LPP1 drastically reduced exogenously added LPA (98.01 Ϯ 0.46% compared with control) (Fig. 3D) . Furthermore, LPS treatment (10 g/ml, 0 -6 h) did not increase LPA generation in either medium or cells (data not shown). These data suggest that the attenuation effect of LPA 1 on LPS-mediated phosphorylation of p38 MAPK and I-kB is not mediated by LPA generation and that a LPA-independent mechanism may regulate the LPS signaling.
LPS induces LPA 1 interaction with CD14. CD14, as a coreceptor, regulates LPS-induced signal transduction (8, 28) . To investigate the role of CD14, MLE12 cells were incubated with neutralizing CD14 antibody (10 g/ml, 6 h), which attenuated LPS-induced phosphorylation of p38 MAPK and I-B (Fig. 4, A and B) . We have previously shown in lung epithelial cells that there is a cross talk between LPA receptor(s) and receptor tyrosine kinases such as epidermal growth factor receptor (EGF-R) (43) and c-Met (44) . Therefore, we examined the potential interaction between LPA 1 and CD14. MLE12 cells treated with LPS revealed enhanced LPA 1 interaction with CD14 in a dose-and time-dependent fashion (Fig.  4, C and D) , however, TLR4 was not detectable in LPA 1 -immunoprecipitated complex (data not shown). Double-fluorescence immunostaining with antibodies to LPA 1 and CD14 revealed that LPS treatment (10 g/ml, 2 h) increased colocalization of LPA 1 (green) and CD14 (red) on plasma membrane (yellow) (Fig. 4E) . Both LPA 1 (39) and CD14 (8, 28) have been shown to be associated in lipid rafts, a functional domain on the cell surface. Disruption of lipid rafts by MBCD blocked the interaction between LPA 1 and CD14 (Fig. 4F) . These results suggested that LPA 1 contributes to LPS-induced signaling through interaction with CD14 in lipid rafts.
LPS modulates expression of LPA receptors in MLE12 and mouse lungs. LPA receptors are widely expressed in various tissues. To investigate the effect of LPS on the expression of LPA receptors in lung tissue, C57/BL6 mice were instilled with LPS intratracheally (1 and 5 mg/kg) for 24 h, and RNA and protein were extracted from lung tissues. Compared with nonchallenged control mice, LPS treatment significantly increased mRNA levels of LPA 1 and LPA 2 , without altering LPA 3 expression (Fig. 5, AϪC) ; however, Western blotting showed that LPS challenge increased protein expression of LPA [1] [2] [3] in lung tissues (Fig. 5, D and E) . The increase in LPA 3 protein expression without altering the mRNA expression may be the result of LPS-increased LPA 3 protein stability. In contrast to in vivo LPS challenge, LPS treatment (10 g/ml, 3-20 h) of MLE12 cells had no effects on LPA receptor expression (data not shown). These results show that LPS modulates expression of LPA receptors in mouse lungs.
LPS challenge increases plasma LPA levels in mice. Our previous study has shown that intratracheal LPS challenge increased LPA levels in BAL fluids (42) . Here, we investigated whether LPS challenge increases LPA levels in mouse plasma. After intratracheal LPS (5 mg/kg body wt) challenge for 24 h, LPA molecular species in plasma were detected and quantified by LC-MS/MS (39) . As shown in Table 1, LPA, 20:4 LPA, and 22:6 LPA were abundant in mouse plasma, which is consistent with earlier findings (50) . LPS challenge significantly increased plasma LPA levels to ϳ1.6-fold (control: 165.76 Ϯ 16.13 pmol/ml; LPS: 262.53 Ϯ 19.22 pmol/ml). Among the LPA molecular species, 18:2 LPA increased ϳ2.6-fold (control: 40.59 Ϯ 4.22 pmol/ml; LPS: 103.71 Ϯ 9.53 pmol/ml), 18:1 LPA increased ϳ2.1-fold (control: 7.32 Ϯ 1.14 pmol/ml; LPS: 15.12 Ϯ 1.48 pmol/ml), and 16:0 LPA increased ϳ1.7-fold (control: 16.54 Ϯ 1.60 pmol/ml; LPS: 27.68 Ϯ 1.52 pmol/ml); however, no significant changes were observed with respect to 22:6 LPA and 20:4 LPA. These results show that LPS challenge in mice modulates plasma LPA levels.
Knock down of LPA 1 in mice reduces LPS-induced acute inflammation. To investigate the role of LPA and LPA receptors in LPS-induced acute inflammation and injury, wild-type and LPA 1 knockout mice were challenged intratracheally with LPS (5 mg/kg body wt) for 24 h. BAL fluids were collected for IL-6, total cell number, and total protein levels. LPS challenge increased the secretion of IL-6 (Fig. 6A) , total cell numbers in BAL fluids (Fig. 6B) , and immune cell infiltration into alveolar spaces (Fig. 6C ) in wild-type mice; however, knock down of LPA 1 attenuated LPS-induced IL-6 secretion (22-30%), total cell numbers in BAL fluids (ϳ26%), and immune cell infiltration (Fig. 6, AϪD) . Elevated protein level in BAL fluids is an index of lung injury. As shown in Fig. 6D , LPS challenge increased BAL fluid total protein levels by ϳ6.0-fold in wildtype mice. Interestingly, the BAL fluid protein levels in LPSchallenged LPA 1 knockout mice were comparable to their wild-type counterparts (Fig. 6D) . These results suggest that LPA and LPA 1 partly contribute to LPS-induced acute inflammation.
Ki16425 attenuates LPS-induced acute lung inflammation. To further substantiate the above observations, C57/BL6 mice were intratracheally injected with 25 l of vehicle (0.1% DMSO PBS) or Ki16425 (5 M dissolved in PBS containing 0.1% DMSO) 1 h before LPS challenge. Ki16425 Mice were intratracheally challenged with lipopolysaccharide (LPS, 5 mg/kg body wt) for 24 h. Plasma was collected, and lipids were extracted. Lysophosphatidic acid (LPA) molecular species were quantified by LC-MS/MS with 17:0 LPA as standard. ajplung.physiology.org pretreatment reduced LPS-induced IL-6 secretion (ϳ44%) (Fig. 7A) , total cell numbers in BAL fluids (ϳ24%) (Fig.  7B) , and immune cell infiltration into alveolar spaces (Fig.  7C) ; however, Ki16425 had no effect on LPS-induced protein levels in BAL fluids (Fig. 7D) . Notably, protein concentrations in BAL fluids in DMSO-or Ki16425-challenged mice were much higher compared with those from PBSchallenged mice. This may be because of the presence of DMSO in PBS, and Ki16425 was dissolved in DMSO. H&E staining does not support epithelial and endothelial barrier disruption by DMSO or Ki16425. These results suggest that inhibition of LPA 1 attenuates LPS-induced inflammation but not pulmonary leak.
DISCUSSION
The current study is aimed at determining the role of LPA 1 in endotoxin-induced inflammation using lung epithelial cells and a murine model of ALI. We found that, in lung epithelial cells, LPA 1 interacted with CD14, a coreceptor for LPS, in lipid rafts in response to LPS treatment. Inhibition or downregulation of LPA 1 attenuated LPS-induced IL-6 secretion. These effects of LPA 1 may not involve the LPA-LPA 1 signaling axis, since reduction of extracellular LPA has no effect on LPS-induced phosphorylation of p38 MAPK and I-kB. LPS challenge increased LPA levels in plasma and BAL fluids and the expression of LPA receptors in lung tissues. Finally, in LPA 1 knockout mice or mice treated with LPA 1 antagonist, LPS-induced inflammation was partly reduced as evidenced by reduced IL-6 levels in BAL and infiltration of immune cells into the lung tissue.
In the lung, LPA levels are upregulated in BAL fluids of asthmatic patients (13) , murine models of Th-2-mediated asthma (47) , bleomycin-induced fibrosis (38) , and LPS-induced ALI (42) . Here, we show that plasma LPA levels are increased in a LPS-induced murine model of ALI. The mechanism(s) of LPA generation in BAL fluids is not clear; however, recent studies suggest a critical role of autotaxin in regulation of LPA levels in plasma and cancer tissues (1, 41) , and our previous study shows that LPS challenge increased autotoxin levels in BAL fluids (42) . LPA is known to signal through G protein-coupled LPA receptors. Although LPS has no effect on LPA receptor expression in MLE12 cells, intratracheal LPS challenge increased LPA receptor expression in lung tissues. It is possible that the LPS-induced increase in LPA receptor expression is the result of neutrophil influx. LPA receptors are expressed in neutrophils, and upregulation of LPA 1 and LPA 2 expression in neutrophils from pneumonia patients has been reported (29) . Further studies are necessary to clarify the mechanisms of increased LPA receptor expression by LPS in lung tissues.
LPA exhibits both pro-and anti-inflammatory effects in airway diseases (46) . The proinflammatory effects of LPA receptors in lung inflammatory diseases have been demonstrated (1, 38, 47) . LPA 1 ϩ/Ϫ -and LPA 2 ϩ/Ϫ -deficient mice exhibited reduced inflammation in an ovalbumin-challenged murine model of asthma (47) , and genetic knock down of LPA 1 (38) and LPA 2 (Zhao, unpublished data) protected mice from bleomycin-induced pulmonary fibrosis. Consistent with these findings, the current study showed that abrogation of LPA 1 either by using LPA 1 knockout mice or by inhibiting LPA 1 in wild-type mice attenuated LPS-induced inflammation. However, it did not prevent LPS-induced protein leakage in BAL fluids, thereby suggesting that vascular permeability is regulated by mechanisms that are independent of LPA 1 . Although LPA has been shown to reduce permeability of human umbilical vein endothelial cells (20) , LPA treatment of human pulmonary endothelial cells with lower expression of LPA receptors had no effects on permeability (Zhao, unpublished data). However, LPA treatment increased lung epithelial barrier integrity (18) , suggesting LPA-mediated specific effects in the epithelium.
It is important to point out that exogenous LPA plays a protective role against endotoxin-induced lung injury. Intratracheal administration of LPA increased the innate immune response at early time points (Ͻ6 h) but not at later time periods (Ͼ12 h) (7), and LPA levels in BAL fluids rapidly returned to near-basal levels because of the short half-life of LPA (48) . Furthermore, recent studies have shown that intravenous injection of LPA followed by intraperitoneal injection of LPS significantly increased mice survival, reduced the tumor necrosis factor-␣ level in BAL fluids, and decreased myeloperoxidase activity in lung by LPS (11) . Intratracheal administration of LPA at 1 h after LPS challenge reduced LPS-induced inflammatory cell infiltration and IL-6 and protein levels in BAL fluids (18) . These effects of exogenous LPA are in contrast to the effects of high levels of endogenous LPA, which are observed in BAL fluids or plasma from murine models of asthma (47) and ALI (42) . These studies suggest that exogenous LPA plays a protective role by increasing transient innate immune responses in the early stage of inflammation, whereas a consistently high level of endogenous LPA promotes inflammation through induction of cytokine release and neutrophil influx via LPA receptor signaling and interaction with LPS/TLR4 signal transduction.
Both LPA and LPS stimulated secretion of cytokines, such as IL-6, in lung epithelial cells. We found that inhibition of LPA 1 attenuated LPS-induced activation of NF-B and p38 MAPK, indicating a role of LPA 1 in LPS-mediated signaling. CD14, a coreceptor for LPS, is known to bind to LPS and LPS-binding protein (LBP) (37) and is wildly expressed in immune cells, including macrophages (37), neutrophils (37) , and lung epithelial cells (37) . We show here that CD14-neutralizing antibody attenuates LPSinduced signal transduction in MLE12 cells. Recent studies demonstrated that, in addition to LBP, CD14 interacted with other proteins, such as surfactant A (32), C (2), and D (32), integrin-␤ 1 (22) , and Mac-1 (27) ; however, the biological role of these interactions has not been well investigated. Here, we demonstrated that inhibition of LPA 1 attenuated LPS-induced signaling pathways of phosphorylation of p38 MAPK and I-kB; however, reduction of LPA levels by overexpression of LPP1 had no effects on LPS-induced signals, indicating that LPA 1 -mediated LPS signaling is independent on its LPA-LPA 1 signaling axis in cell culture conditions. However, our in vivo data show that LPS increases LPA generation in plasma and BAL fluids and LPA receptor expression in lung tissues, suggesting that LPA generation and the LPA-LPA 1 axis may regulate part of LPS signaling in the murine model of lung injury. This may because of involvement of other immune cells, such as neutrophils and macrophages, in lung tissues. Furthermore, we demonstrated that CD14 binds to LPA 1 in lipid rafts in response to LPS treatment, suggesting a novel role for LPA 1 /CD14 in LPS-induced signaling via TLR4 in airway inflammation. LPA receptor(s) are known to interact with receptor tyrosine kinases, and we have shown that LPA receptors cross talk with EGF-R (52) and c-Met (53) in human bronchial epithelial cells, and LPA 1 also interacts with integrin-␤ 4 (42) .
In summary, the current study for the first time demonstrated that LPA 1 is involved in LPS-induced activation of the NF-B pathway, p38 MAPK, and IL-6 secretion through interaction with CD14, a coreceptor of LPS. In vivo experiments showed that LPS treatment increased LPA levels in plasma, and knock down of LPA 1 reduced LPS-induced IL-6 levels. These results support a significant role for LPA 1 in promoting LPS-induced acute lung inflammation.
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